The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Assessing & improving the symptoms of patients with MPNs
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the importance of improving strategies to measure and treat the symptoms of patients with myeloproliferative neoplasms (MPNs). Dr Masarova outlines the benefits of the MPN-10 tool, which is utilized to assess the symptoms of patients with MPNs. Dr Masarova also highlights that some therapies, including interferon, which evidently modify the disease do not improve symptoms of MPNs. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
